CD274 and neoplasm: While neither intratumoral CCL5 nor anti-PD-L1 (atezolizumab) alone inhibited tumor growth, CCL5 in combination with anti-PD-L1 significantly reduced tumor growth relative to all individual arms (p < 0.05; Fig. 5e, f).